Bayer Increases Chinese Presence With Topsun Cough/Cold Buy
This article was originally published in The Tan Sheet
Executive Summary
Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25
You may also be interested in...
Bayer closes Topsun deal
Bayer closes its $157 million acquisition of part of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co.'s OTC assets, the firms say July 3. Bayer gained the Chinese firm compound pseudoephedrine hydrochloride tablets, which analysts expect to produce $48 million in sales this year. Bayer will also pay a $24 million bonus at the end of the year as part of the deal (1"The Tan Sheet" Oct. 30, 2006, p. 9)...
Bayer
Aleve pain reliever sales advanced 27.5% to $302.3 mil. (E1=$1.33) in 2006 (ended Dec. 31), Bayer announces March 15. One-A-Day achieved sales growth of 5.1% to $165.1 mil. and Alka-Seltzer revenues increased 6.3% to $101 mil. for the year, firm adds. The brands helped drive sales of Bayer's Consumer Health Consumer Care Division, which jumped 7.5% to $3.37 bil. for the year, the company reports, noting it doubled sales of its OTC pharmaceuticals franchise during the year. The Consumer Health segment had net sales of $5.66 bil., representing growth of 8.1%. The company is continuing expansion of the Consumer Health division abroad, particularly in China, with the recent purchase of OTC company Topsun's cough/cold portfolio (1"The Tan Sheet" Oct. 30, 2006, p. 9). The HealthCare group's net sales grew 46.6% to $15.62 bil., and earnings before interest, taxes, depreciation and amortization before special items soared 75.7% to $3.48 bil. Bayer is targeting underlying EBITDA margin growth of about 27% in HealthCare in 2009...
Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains
Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27